Consensus Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
30.45 USD +0.73% Intraday chart for Royalty Pharma plc +0.13% +8.40%

Evolution of the average Target Price on Royalty Pharma plc

Price target over the last 5 years

History of analyst recommendation changes

923e430d5de753dd4c104.tMYtW00IgN39Tp5pjKMKkC9j1pzDW-JWp4DoB_ia2SM.875GaXRu4azLC6kz9edB8V4tps2uMqEu9cKna83cl0zrl04IIn7SjdAZ_Q~8790b207a30aed951b07580615bddf21
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $50 From $56, Keeps Buy Rating MT
Morgan Stanley Cuts Price Target on Royalty Pharma to $46 From $57, Keeps Overweight Rating MT
ANALYST RECOMMENDATIONS : Adobe, Amgen, Blackrock, IBM, Ulta Beauty... Our Logo
Morgan Stanley Adjusts Price Target on Royalty Pharma to $57 From $54, Maintains Overweight Rating MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $54 From $53, Maintains Overweight Rating MT
UBS Adjusts Royalty Pharma Price Target to $41 From $44, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $53 From $52, Maintains Overweight Rating MT
UBS Adjusts Royalty Pharma Price Target to $44 From $48, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $52 From $50, Maintains Overweight Rating MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $50 From $48, Maintains Overweight Rating MT
Fitch Affirms Royalty Pharma plc at 'BBB-'; Outlook Stable AQ
Bank of England lifts rates by 25 basis points AN
UBS Adjusts Royalty Pharma's Price Target to $48 From $51, Maintains Buy Rating MT
Morgan Stanley Cuts Price Target on Royalty Pharma to $51 From $54, Maintains Overweight Rating MT
UBS Adjusts Royalty Pharma Price Target to $51 From $50, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $54 From $51, Maintains Overweight Rating MT
JPMorgan Chase Adjusts Royalty Pharma's Price Target to $52 From $50, Keeps Overweight Rating MT
Morgan Stanley Increases Royalty Pharma's Price Target to $51 From $48, Maintains Overweight Rating MT
Goldman Sachs Adjusts Price Target for Royalty Pharma to $56 From $55, Maintains Buy Rating MT
Citigroup Adjusts Price Target on Royalty Pharma to $60 From $50, Reiterates Buy Rating MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $55 From $57, Maintains Buy Rating MT
Tigress Financial Adjusts Royalty Pharma's Price Target to $57 From $52, Maintains Buy Rating MT
UBS Raises Royalty Pharma's Price Target to $50 From $47, Buy Rating Maintained MT
Fitch Affirms Royalty Pharma at 'BBB-'; Outlook Stable AQ
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
30.45 USD
Average target price
45.4 USD
Spread / Average Target
+49.10%
High Price Target
60 USD
Spread / Highest target
+97.04%
Low Price Target
37 USD
Spread / Lowest Target
+21.51%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Royalty Pharma plc

JPMorgan Chase
Goldman Sachs
Morgan Stanley
UBS
Citigroup
Tigress Financial
Scotiabank
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings